Alembic Pharmaceuticals
Alembic Pharmaceuticals
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
-
Shareholder Return454%
-
Sales Growth27%
-
Return on Equity45 %
Why Super 50
Shift in focus from commodity APIs to higher potential formulations. A strong supply chain to build customer trust. Increasing investment in R&D.
